{"schema_version":"secwatch.filing_event.v1","accession":"0001055726-25-000056","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.216523+00:00","generated_at":"2026-05-17T14:13:24.471893+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inovio Q2 net loss narrows to $23.5M; BLA for INO-3107 on track for 2H25 submission","bullets":["Net loss $23.5M ($0.61/share) vs $32.2M ($1.19/share) YoY; total operating expenses $23.1M down from $33.3M.","Completed CELLECTRA 5PSP device DV testing; requested rolling BLA submission for INO-3107 by year end.","Cash, cash equivalents, and short-term investments $47.5M at June 30; plus $22.5M from July offering, supporting ops into Q2 2026.","Long-term INO-3107 data published: 86% of patients had 50-100% reduction in surgeries by Year 2; mean surgeries reduced from 4.1 to 0.9.","R&D expenses fell to $14.5M from $23.1M, reflecting lower drug manufacturing and clinical costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001055726-25-000056","json":"https://secwatch.observer/filing/0001055726-25-000056.json","markdown":"https://secwatch.observer/filing/0001055726-25-000056.md","text":"https://secwatch.observer/filing/0001055726-25-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/0001055726-25-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000056/ino-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:13:24.471893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}